The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

GSK plc (NYSE:GSK) is one of the 11 best European stocks to invest in. On June 24, the company announced receipt of FDA ...

The American College of Rheumatology has updated its systemic lupus erythematosus treatment guidelines for the first time ...

Enpatoran, a TLR7/8 inhibitor, demonstrated clinically meaningful improvements in disease activity among patients with ...

WILLOW (NCT05162586) is a randomized, double-blind, placebo-controlled Phase 2 proof of concept and dose-finding study designed to evaluate the efficacy and safety of enpatoran in patients with ...

Treatment of systemic lupus erythematosus needs to fulfill a number of objectives Symptoms of systemic lupus erythematosus (SLE) must be brought under control to avert immediate consequences and ...

Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an ...

There is a substantial unmet treatment need for the estimated 70-80% of SLE patients who experience active cutaneous ... oral, novel TLR7/8 inhibitor in systemic lupus erythematosus (SLE).

Hydroxychloroquine is tied to reduced preeclampsia risk but not preterm birth risk in pregnant patients with lupus in a ...

Magnetic resonance imaging (MRI) findings such as inflammatory-type lesions and myelopathies are significantly associated with attribution of neuropsychiatric (NP) events to systemic lupus ...

A scoping review highlights key sex-related differences in SLE, showing more severe organ damage in men and distinct symptom and treatment patterns across sexes.

Researchers from EMD Serono and global collaborators shared promising results from Cohort B of the phase II trial of the WILLOW study.